TrialBritish journal of cancer2018

A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma.

D H Palmer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.